Amarin Pharma, FDA Talk Settlement Of Off-Label Lawsuit After Injunction
NEW YORK — Amarin Pharma Inc. and the Food and Drug Administration are exploring the possibility of settling Amarin’s off-label speech lawsuit, counsel for the drug company told a New York...To view the full article, register now.
Already a subscriber? Click here to view full article